Quanterix to Participate in the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Task Force
Quanterix Corporation (QTRX)
US:NASDAQ Investor Relations:
ir.quanterix.com/investor-relations
Company Research
Source: Business Wire
Company to provide industry perspective on the use of emerging blood-based biomarkers tests in Alzheimer’s disease clinical trials. BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced plans to participate in the upcoming 15th Clinical Trials on Alzheimer’s Disease (CTAD) Task Force in San Francisco, California from November 29 to December 2, 2022. Quanterix CEO Masoud Toloue is scheduled to present on Tuesday, November 29 at 9:55 a.m. PST, along with a panel of assay industry leaders, on leveraging the use of blood-based biomarkers rather than the current gold standard of positron emission tomography (PET). PET is an expensive testing modality, whereas less invasive, less expensive blood-based biomarkers have demonstrated promise to facilitate more efficient clinical trial enrollment and as a convenient monitoring test of drug treatment effects. The Task Force pan
Show less
Read more
Impact Snapshot
Event Time:
QTRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QTRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QTRX alerts
High impacting Quanterix Corporation news events
Weekly update
A roundup of the hottest topics
QTRX
News
- Investing in Quanterix (NASDAQ:QTRX) a year ago would have delivered you a 111% gain [Yahoo! Finance]Yahoo! Finance
- Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure [Yahoo! Finance]Yahoo! Finance
- Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing InfrastructureBusiness Wire
- Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag [Yahoo! Finance]Yahoo! Finance
- Quanterix Co. (NASDAQ: QTRX) had its price target raised by analysts at Scotiabank from $30.00 to $32.00. They now have a "sector outperform" rating on the stock.MarketBeat
QTRX
Earnings
- 2/29/24 - Miss
QTRX
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form ARS
- 4/15/24 - Form DEF
- QTRX's page on the SEC website